CO vs. VMD, VXRT, CRDL, CNTX, GOSS, SGMT, SYRS, TELA, ARAY, and XFOR
Should you be buying Global Cord Blood stock or one of its competitors? The main competitors of Global Cord Blood include Viemed Healthcare (VMD), Vaxart (VXRT), Cardiol Therapeutics (CRDL), Context Therapeutics (CNTX), Gossamer Bio (GOSS), Sagimet Biosciences (SGMT), Syros Pharmaceuticals (SYRS), TELA Bio (TELA), Accuray (ARAY), and X4 Pharmaceuticals (XFOR). These companies are all part of the "medical" sector.
Global Cord Blood (NYSE:CO) and Viemed Healthcare (NASDAQ:VMD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, community ranking, media sentiment and analyst recommendations.
Global Cord Blood received 339 more outperform votes than Viemed Healthcare when rated by MarketBeat users. Likewise, 74.51% of users gave Global Cord Blood an outperform vote while only 42.86% of users gave Viemed Healthcare an outperform vote.
74.2% of Viemed Healthcare shares are owned by institutional investors. 0.5% of Global Cord Blood shares are owned by company insiders. Comparatively, 20.0% of Viemed Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Global Cord Blood and Global Cord Blood both had 3 articles in the media. Viemed Healthcare's average media sentiment score of 1.88 beat Global Cord Blood's score of 0.22 indicating that Viemed Healthcare is being referred to more favorably in the news media.
Global Cord Blood has higher revenue and earnings than Viemed Healthcare. Global Cord Blood is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.
Viemed Healthcare has a net margin of 5.32% compared to Global Cord Blood's net margin of 0.00%. Viemed Healthcare's return on equity of 9.32% beat Global Cord Blood's return on equity.
Global Cord Blood has a beta of 0.16, indicating that its stock price is 84% less volatile than the S&P 500. Comparatively, Viemed Healthcare has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500.
Summary
Viemed Healthcare beats Global Cord Blood on 10 of the 15 factors compared between the two stocks.
Get Global Cord Blood News Delivered to You Automatically
Sign up to receive the latest news and ratings for CO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Global Cord Blood Competitors List
Related Companies and Tools
